FDA Approves Vonjo (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

SEATTLE, Feb. 28, 2022 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved Vonjo (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary…Original Article